Past, present and future of erythropoietin use in the elderly

International Urology and Nephrology

Volumn 33, Issue 1, 2001, Pages 187-193

  De Francisco, Angel L M ^a   Fernandez Fresnedo, Gema ^a   Rodrigo, Emilio ^a   Piñera, Celestino ^a   Heras, Milagros ^a   Palomar, Rosa ^a   Ruiz, Juan C ^a   Arias, Manuel ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ERYTHROPOIETIN;

AGED; BRAIN FUNCTION; BRAIN TISSUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; ELDERLY CARE; FOLIC ACID DEFICIENCY; GERIATRIC DISORDER; HEART LEFT VENTRICLE HYPERTROPHY; HEMATOCRIT; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INCIDENCE; IRON DEFICIENCY ANEMIA; KIDNEY FAILURE; MEMORY CONSOLIDATION; OXYGEN SUPPLY; PERCEPTIVE DISCRIMINATION; PHYSICAL PERFORMANCE; POPULATION RISK; QUALITY OF LIFE; REVIEW; SEXUAL FUNCTION; STIMULUS RESPONSE; TASK PERFORMANCE; TISSUE PERFUSION; VITAMIN DEFICIENCY; AGE; CHRONIC KIDNEY FAILURE; FEMALE; MALE; METHODOLOGY; PROGNOSIS; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; ERYTHROPOIETIN; FEMALE; HUMAN; KIDNEY FAILURE, CHRONIC; MALE; PROGNOSIS; QUALITY OF LIFE; RENAL DIALYSIS; RISK ASSESSMENT; TREATMENT OUTCOME; HUMANS;

EID: 0036049401     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014478704766     Document Type: Review

References (47)

1. Towards the millenium: A history of renal anaemia and the optimal use of epoetin
2. Historical review on the use of recombinant human erythropoietin in chronic renal failure
3. The future of r-HuEPO
4. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention
5. Health related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients
6. How should anaemia be managed in predialysis patients
7. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients
8. Impact of left ventricular hypertrophy on end stage renal disease
9. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin
10. Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin
11. Renewed cardiovascular dynamics induced by recombinant erythropoietin administration
12. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: A prospective study
13. Cardiovascular consequences of renal anaemia and erythropoietin therapy
14. Effects of erythropoietin on blood pressure
15. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin
16. Effects of epoetin on vascular biology
17. Long term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis
18. Antiplatelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients
19. Antiplatelet therapy decreases the incidence of erythropoietin induced hypertension in predialysis patients
20. ACE inhibitors do not decrease rHuEPO response in patients with end stage renal disease
21. NKF-DOQI Clinical Practice Guidelines for the treatment of anemia of chronic renal failure guidelines: V. Inadequate Epoetin response: Guidelines 20-22
22. NKF-DOQI Clinical Practice Guidelines for the treatment of anemia of chronic renal failure guidelines: III. Iron support: Guidelines 5-10
23. Iron balance in hemodialysis patients
24. A randomized controlled study of iron supplementation in patients treated with erythropoietin
25. Correction of uremic iron deficiency anemia in hemodialyzed patients: A prospective study
26. Dialysate iron therapy: Infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis
27. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia
28. Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: A prospective study
29. L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin
30. Anemia and carnitine supplementation in hemodialyzed patients
31. Role of cytoquines in the response to erythropoietin in hemodialysis patients
32. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients
33. Subcutaneous compared with intravenous epoietin in patients receiving hemodialysis
34. NKF-DOQI clinical practice guidelines for anemia of chronic renal failure IV administration of epoetin
35. Probability of thrombosis of vascular access among hemodialysis patients treated with recombinant human erythropoietin
36. Erythropoietin therapy improves graft patency with no increased incidence of thrombosis or thrombophlebitis
37. Normalization of haemoglobin: Why not?
38. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
39. Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients
40. Normalizing hematocrit in dialysis patients improves brain function
41. Gene therapy for renal anemia in mice with polycystic kidney using an adenovirus vector encoding the human erythropoietin gene
42. Erythropoietin loaded microspheres prepared from biodegradable LPLG-PEO-LPLG triblock copolymers: Protein stabilization and in vitro release properties
43. Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts
44. New epoetin molecules and novel therapeutic approaches
45. European best practice guidelines for the management of anaemia in patients with chronic renal failure